Jay Carter, ABELSONTAYLOR
When economizing on agency spend, a key question needs to be answered: "Are you getting great value for your promotion?"
Jay Carter
SENIOR VICE PRESIDENT, DIRECTOR OF CLIENT SERVICES | ABELSONTAYLOR
Whenever I discuss the issue of economizing on agency spend, two key questions need to be answered. First: "Are you getting great value for your promotion?" (That is, does it work as well as it could?) If the answer is no, a savvy and cost-conscious marketer should focus on the quality of the core promotion first. Economy comes from cutting programs that don't work, not by cutting the margins of a trusted partner who is doing the job you ask of them.
Jay Carter
The second question is "Are my processes as efficient as they can be?" While every organization needs to be effective in gaining the advice and consent of a medical-regulatory-legal team, frequently the number of steps taken are far more extensive than productivity would permit. For a large pharma client on a billion-dollar brand, a Six Sigma process was undertaken jointly by the client and AbelsonTaylor. It uncovered inefficiencies that, when addressed, reduced process costs by 17 percent. The main culprits? Poor initial direction by unseasoned brand managers and a need by junior staff to have perfectly clean promotional materials produced for each escalating review by their management. If senior marketers want to cut their costs, they can do so by undertaking efficiency training for their promotions staff on how to cut the waste out of their own process.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
